"Test Biogen (BIIB) and Japanese partner Eisai may be at odds in developing a treatment for Alzheimer's disease, an analyst said Monday after a paradoxical presentation last week. The two are collaborating on BAN2401, an experimental Alzheimer's disease drug. But test results unveiled last week showed BAN2401 may only work in a small subset of patients. Leerink analyst Geoffrey Porges suggested Biogen would be better off focusing on its own drug, aducanumab. Most companies would likely advance BAN2401 into Phase 3 studies, Porges said in a report to clients. But aducanumab seemingly has a better profile than BAN2401. Both belong to the same class of drugs which aim to reduce the buildup of toxic plaque in the brain.""
Posts published in “Business”
"Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”)(NYSE: ABBV), a research-based global biopharmaceutical company, today announced a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. Alzheimer’s and Parkinson’s diseases are associated with the accumulation of misfolded, toxic proteins, which are believed to cause impaired function and death of nerve cells in the brain. DUBs play an important role in keeping a cell healthy by regulating the degradation of these proteins. There are over 100 different DUBs in humans. By modulating specific DUBs within the brain, AbbVie and Mission are aiming to develop potential therapeutics that enable the degradation of these toxic proteins and prevent their accumulation."
"Investing in companies taking an anti-amyloid approach are not likely to produce high dividends (literally and figuratively) while investing in companies like Anavex and Neurotrope may eventually pay off. Amyloid oligomers are one of several factors that lead to nitro-oxidative stress in Alzheimer's disease and they do not reverse that stress. At the recent CTAD conference in Barcelona, Spain a number of companies presented new data regarding their Alzheimer’s drug candidates. Much of the attention focused on Biogen (BIIB), but other companies may be pursuing more fruitful strategies against Alzheimer’s disease. In many cases, results reflect the likely mechanisms of the disease whether its Biogen’s efforts to remove amyloid oligomers, Anavex’s (AVXL) focus on inhibiting intracellular calcium release, or Neurotrope’s (NTRP) hopes founded on the activation of protein kinase C. To a degree, each company’s efforts are linked to the chain of events that leads to the onset and progression of Alzheimer’s disease."
Due to management changes the overall state of the company seems to be turmoil, and it is making questionable decisions around drug studies according the author.
From the outset, a dementia diagnosis necessitates services and care that bring about a mountain of expenses.
Following a dementia diagnosis, people generally live an average of 4.5 years.
Even for those with supplemental long-term care insurance, these care costs can be significant.
Planning ahead can make all the difference between effectively managing the financial burden of a dementia diagnosis and sustaining severe financial hardship.
The big pictureIf you or a loved one is diagnosed with any form of dementia, the financial stakes are high.
Ionis Pharmaceuticals (IONS) rocketed in early trading Friday after announcing a $1 billion deal with Biogen (BIIB) to develop treatments for neurological diseases like dementia, following up the success they've had with Spinraza.
The firms plan to work on neurological diseases including dementia, neuromuscular diseases, movement disorders, ophthalmology, inner-ear diseases and neuropsychiatry.
Biogen And Ionis Deepen PartnershipUnder the terms of the deal, Biogen will pay Ionis $1 billion.
The deal announced Friday extends the collaboration under which the two companies developed Spinraza, a treatment for spinal muscular atrophy.
"There is no better partner for Ionis to develop new antisense drugs to treat neurological diseases than Biogen," Ionis Chief Executive Stanley Crooke said in a prepared statement.
"With this cooperative research program, we are proud to continue to innovate by exploring the use of Trappsol® Cyclo™ in the treatment of Alzheimer's disease."
Cholesterol has been linked to the formation of amyloid beta plaques, one of the hallmarks of Alzheimer's disease.
"I am excited for the opportunity to work with CTD on this potential new therapeutic approach in Alzheimer's disease.
The effects of cyclodextrin in Niemann-Pick Disease Type C and pre-clinical studies suggest a potential effect in Alzheimer's disease," said Dr. Kerwin.
"Alzheimer's disease affects millions and currently has no cure or disease modifying therapy.
HIGH POINT — VTV Therapeutics Inc. saw its stock price fall by more than 65 percent in after-market trading Monday after it disclosed disappointing results from the clinical trial of an experimental Alzheimer’s medication.
The High Point-based company announced that the Phase 3 clinical trial assessing the effects of the drug Azeliragon in patients with mild Alzheimer’s disease failed to achieve either co-primary endpoint.
Shares of VTV Therapeutics plunged 65 percent to $1.14, down $2.12 per share, in after-hours trading as of 6:15 p.m.
VTv Therapeutics announced the company will terminate all current clinical trials of azeliragon, which included two separate Phase 3 trials each with about 400 participants per trial.
More information about vTv Therapeutics can be found online.
9932394 entitled, “Single Chain Intrabodies that Alter Huntingtin Mutant Degradation”.
Issued claims cover composition of matter as well as both the Huntingtin and Tau protein targets with the potential for treatment of both Huntington’s and Alzheimer’s diseases.
Our current focus is on Huntington’s disease where we are planning IND enabling studies,” said Lee Henderson, Vybion CEO.
Vybion scientists have previously published findings demonstrating that INT41 accelerates degradation of the toxic gain of function fragment of the mutant huntingtin protein thereby decreasing gene dysregulation and perinuclear aggregation caused by this huntingtin protein degradation fragment (http://dx.doi.org/10.1155/2016/7120753).
About Vybion, Inc. Vybion is a development stage Company with proprietary technologies for Intrabody development currently pursuing strategies to treat neurodegenerative diseases such as Huntington's, SBMA and SCA1, 3, 7 and Alzheimer’s.
Alzheimer’s disease (AD) is the most common form of dementia, affecting more than five million people in the US alone; it’s also the sixth leading cause of deaths in the country.
Here’s a closer look at those Alzheimer’s disease treatment stocks.
Actinogen Medical (ASX:ACW)Market cap: AUD$38.11 million; current share price: AUD$0.05First on our Alzheimer’s disease treatment stocks list is Actinogen Medical.
Axsome Therapeutics (NASDAQ:AXSM)Market cap: $170.18 million; current share price: $1.58Middle of the pack on our Alzheimer’s disease treatment stocks list is Axsome Therapeutics.
5. vTv Therapeutics (NASDAQ:VTVT)Market cap: $191.62 million; current share price: $5.84Closing out our Alzheimer’s disease treatment stocks list is vTv Therapeutics.